Universität zu Köln

Journal Article

Abdulla, D. S. Y., Nogova, L., Riedel, R., Scheftler, M., Fischer, R. N., Michels, S., Heydt, C., Ihle, M. A., Fassunke, J., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2018). NTRK1/2/3 gene rearrangements define a new and clinically actionable molecular subset of oncogene-driven cancers. Oncol. Res. Treat., 41. S. 293 - 294. BASEL: KARGER. ISSN 2296-5262

Ackermann, S., Cartolano, M., Hero, B., Roderwieser, A., Bartenhagen, C., Rosswog, C., Hertwig, F., Simon, T., Eggert, A., Speleman, F., Buettner, R., O'Sullivan, R., Thomas, R., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J., Peifer, M. and Fischer, M. (2018). A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma. Pediatr. Blood Cancer, 65. S. S87 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Ackermann, S., Cartolano, M., Hero, B., Roderwieser, A., Bartenhagen, C., Rosswog, C., Hertwig, F., Simon, T., Eggert, A., Speleman, F., Buettner, R., O'sullivan, R., Thomas, R., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J., Peifer, M. and Fischer, M. (2018). A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma. Pediatr. Blood Cancer, 65. S. S234 - 1. HOBOKEN: WILEY. ISSN 1545-5017

Adam, A. C. and Buettner, R. (2016). Compromised liver regeneration as an early step in hepatocarcinogenesis. Virchows Arch., 469. S. S86 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Alidousty, C., Baar, T., Martelotto, L. G., Heydt, C., Wagener, S., Fassunke, J., Duerbaum, N., Scheel, A., Frank, S., Holz, B., Binot, E., Kron, A., Merkelbach-Bruse, S., Ihle, M., Wolf, J., Buettner, R. and Schultheis, A. M. (2018). Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC; a central role of TP53 mutations. Virchows Arch., 473. S. S315 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Ansen, S., Schultheis, A., Hellmich, M., Leenders, F., Zander, T., Michels, S., Brockmann, M., Stoelben, E., Groen, H., Timens, W., Buettner, R., Thomas, R. K., Perner, S. and Wolf, J. (2014). PD-L1 expression and genotype in Non-Small Cell Lung Cancer (NSCLC). Oncol. Res. Treat., 37. S. 5 - 7. BASEL: KARGER. ISSN 2296-5262

Bos, M., Gardizi, M., Heukamp, L. C., Merkelbach-Bruse, S., Schildhaus, H. -U., Scheffler, M., Nogova, L., Mattonet, C., Serke, M., Randerath, W. J., Gerigk, U., Bruemmendorf, T. H., Krueger, S., Panse, J., Kaminski, B., Reiser, M., Buettner, R. and Wolf, J. (2014). The Network Genomic Medicine: A prospective comprehensive molecular screening network for implementation of personalized lung cancer therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262

Bos, M., Gardizi, M., Heukamp, L. C., Schildhaus, H. -U., Merkelbach-Bruse, S., Nogova, L., Scheffler, M., Serke, M., Schulz, H., Krueger, S., Bruemmendorf, T. H., Panse, J., Schmitz, S., Gerigk, U., Randerath, W. J., Ko, Y. D., Kambartel, K., Huenerlituerkoglu, A. -N., Buettner, R. and Wolf, J. (2014). A retrospective analysis of overall survival of ALK translocation - and of EGFR mutation positive NSCLC patients treated with and without personalized therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262

Brandes, V, Scheffler, M., Kambartel, K., Ortiz-Cuaran, S., Scheel, A., Michels, S., Nogova, L., Fischer, R., Abdulla, D., Merkelbach-Bruse, S., Buettner, R., Sos, M. L. and Wolf, J. (2016). Targeting HER2-and MET co-amplification in patients with EGFR mutation resistant to EGFR-TKI therapy. Oncol. Res. Treat., 39. S. 172 - 173. BASEL: KARGER. ISSN 2296-5262

Buettner, R. (2014). Just another brick in the wall: unravelling the epigenetic mechanism underlying tumour initiation of testicular germ cell cancer. Br. J. Cancer, 110 (3). S. 549 - 551. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827

Buettner, R. (2015). Obituary Robert Fischer 07.02.1930-18.08.2015, has works published, Professor. Pathologe, 36. S. 247 - 248. NEW YORK: SPRINGER. ISSN 1432-1963

Buettner, R. and Friedrichs, N. (2019). Hereditary colon cancer in Lynch syndrome/HNPCC syndrome in Germany. Pathologe, 40 (6). S. 584 - 592. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Buettner, R. and Heydt, C. (2013). Biomarker analysis from a pathologist's view. Founding the rationale for personalised treatment of lung cancer. Bundesgesundheitsblatt-Gesund., 56 (11). S. 1502 - 1509. NEW YORK: SPRINGER. ISSN 1437-1588

Buettner, R., Wolf, J. and Kron, A. (2019). The national Network Genomic Medicine (nNGM). Model for innovative diagnostics and therapy of lung cancer within a public healthcare system. Pathologe, 40 (3). S. 276 - 281. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Castiglione, R., Alidousty, C., Wagener, S., Holz, B., Kron, A., Wolf, J., Merkelbach-Bruse, S., Reinhardt, C., Buettner, R. and Schultheis, A. M. (2018). Genetic MET alterations in non-small cell lung cancer: biologic differences and analogies. Virchows Arch., 473. S. S17 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Castiglione, R., Ihle, M. A., Heydt, C., Alidousty, C., Schultheis, A., Merkelbach-Bruse, S., Hermsen, M., Buettner, R. and Franchi, A. (2017). Molecular characterisation of sinunasal carcinomas. Virchows Arch., 471. S. S150 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Castiglione, R., Ihle, M. A., Merkelbach-Bruse, S., Hartmann, W. and Buettner, R. (2016). EGFR mutations in sinonasal Squamous Cell Carcinoma (SCC) and papilloma. Virchows Arch., 469. S. S195 - 2. NEW YORK: SPRINGER. ISSN 1432-2307

Cordts, Y., Wu, F., Fan, J., Odenthal, M., Buettner, R. and Zhou, C. (2021). COMPREHENSIVE PROFILING OF TUMOR HETEROGENEITY AND ITS MICROENVIRONMENT IN ADVANCED NON-SMALL CELL LUNG CANCER AT SINGLE CELL RESOLUTION. J. Immunother. Cancer, 9. S. A9 - 1. LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426

Dietlein, F., Kalb, B., Jokic, M., Torgovnick, A., Schmitt, A., Buettner, R., Thomas, R. and Reinhardt, H. C. (2015). Combined Chk1-and MK2-inhibition displays robust synergy in KRAS-mutant cancer. Oncol. Res. Treat., 38. S. 169 - 170. BASEL: KARGER. ISSN 2296-5262

Dietmaier, W., Buettner, R. and Rueschoff, J. (2019). Microsatellite instability. Review of methods and applications. Pathologe, 40 (3). S. 313 - 328. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Eisert, A., Scheffier, M., Gogl, L., Frank, R., Scheel, A., Merkelbach-Bruse, S., Michels, S., Fischer, R., Buettner, R. and Wolf, J. (2015). Clinical and genetic presentation of high-level cMET-amplified Non-small cell lung cancer (NSCLC) with adenocarcinoma histology. Oncol. Res. Treat., 38. S. 16 - 17. BASEL: KARGER. ISSN 2296-5262

Eisert, A., Scheffler, M., Michels, S., Schultheis, A., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y. -D, Gerigk, U., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications. Oncol. Res. Treat., 37. S. 8 - 9. BASEL: KARGER. ISSN 2296-5262

Eisert, A. K., Scheffler, M., Michels, S., Schultheis, A., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y., Gerigk, U., Geist, T., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). GENETIC VARIABILITY AND CLINICAL PRESENTATION OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MET-AMPLIFICATIONS. Ann. Oncol., 25. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Fischer, A. K., Reuter-Jessen, K., Schildhaus, H-U, Hugo, T., Scheel, A. H., Merkelbach-Bruse, S., Heinmoeller, E., Buettner, R., Jasani, B., Walbeck, J., Rueschoff, J. and Middell, P. (2020). Development of high-risk HPV associated cervical dysplasia despite HPV-vaccination: a regional dysplasia center cohort study. Eur. J. Gynaecol. Oncol., 41 (1). S. 80 - 85. WAN CHAI: IMR PRESS. ISSN 0392-2936

Fischer, R. N., Abdulla, D., Michels, S., Nogova, L., Brandes, V, Scheffler, M., Schaeffer, S., Scheel, A., Thurat, M., Vehreschild, M., Thomas, R., von Bergwelt-Baildon, M., Buettner, R. and Wolf, J. (2016). Bioluma: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer - A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition. Oncol. Res. Treat., 39. S. 92 - 94. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., George, J., Schaefer, S., Scheel, A., Schloesser, H., Vehreschild, M., von Bergwelt-Baildon, M., Nogova, L., Abdulla, D. S. Y., Michels, S., Riedel, R., Scheffler, M., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kambartel, K., Kern, J., Kopp, H-G, Neukirchen, J., Overbeck, T. R., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Buettner, R., Thomas, R. and Wolf, J. (2018). BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer. Oncol. Res. Treat., 41. S. 270 - 272. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., George, J., Scheel, A., Schloesser, H., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kern, J. K., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Michels, S., Nogova, L., Riedel, R., Weber, J-P., Buettner, R., Thomas, R. and Wolf, J. (2022). BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort. Ann. Oncol., 33 (7). S. S1025 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Fischer, R. N., Scheel, A. H., Rothschild, S., I, Schloesser, H. A., Wolf, J., Buettner, R., Ansen, S. and von Bergwelt-Baildon, M. (2015). Tumor-infiltrating B lymphocytes characterized by CD79a and MUM1 independently predict outcome in patients with non-small cell lung cancer. Oncol. Res. Treat., 38. S. 13 - 14. BASEL: KARGER. ISSN 2296-5262

Frangenberg, A., Starbatty, B., Berressem, S., Frangenberg, A., Sueptitz, J., Hayn, A., Hagmeyer, L., Wragge, S., Hellmessen, K., Merkelbach-Bruse, S., Ueckeroth, F., Hekmat, K., Frank, K., Randerath, W., Buettner, R. and Wolf, J. (2018). Implementation of Next Generation Sequencing-based Molecular Diagnostics in a Lung Cancer Center Tumor Board. Oncol. Res. Treat., 41. S. 117 - 118. BASEL: KARGER. ISSN 2296-5262

Frank, R., Scheffler, M., Michels, S., Eisert, A., Fischer, R., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y. D., Gerigk, U., Geist, T., Heukamp, L., Buettner, R. and Wolf, J. (2015). KEAP1-mutations and NFE2L2-mutations in patients with non-small cell lung cancer (NSCLC). Eur. J. Cancer, 51. S. S645 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Frank, R., Scheffler, M., Michels, S., Eisert, A., Gogl, L., Fischer, R., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y. -D, Gerigk, U., Geist, T., Heukamp, L., Buettner, R. and Wolf, J. (2015). KEAP1-mutations and NFE2L2-mutations in patients with non-small cell lung cancer (NSCLC). Oncol. Res. Treat., 38. S. 268 - 269. BASEL: KARGER. ISSN 2296-5262

Frank, R., Scheffler, M., Michels, S., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y. -D, Gerigk, U., Geist, T., Heukamp, L., Buettner, R. and Wolf, J. (2014). Occurrence and characteristics of KEAP1-mutations in patients with non-small cell lung cancer (NSCLC). Oncol. Res. Treat., 37. S. 8 - 9. BASEL: KARGER. ISSN 2296-5262

Fries, J., Buchner, D., Chang, D. -H., Scheel, A., Buettner, R., Hoelscher, A. and Drebber, U. (2016). Phlebosclerosis of submucosal veins leading to ischemic necrosis of the large bowel: The first reported European case of so-called phlebosclerotic colitis with unusual features. Virchows Arch., 469. S. S264 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics. Ann. Oncol., 33. S. S56 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R. N., Riedel, R., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). Small-scale ROS1 aberrations: Functional impact and therapeutic potential. Ann. Oncol., 33 (8). S. S1386 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Gogl, L., Scheffier, M., Ihle, M., Michels, S., Fischer, R., Serke, M., Gerigk, U., Woempner, C., Krueger, S., Kaminsky, B., Schulte, W., Hoeffken, G., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2015). Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations. Oncol. Res. Treat., 38. S. 269 - 270. BASEL: KARGER. ISSN 2296-5262

Gogl, L., Scheffler, M., Ihle, M., Michels, S. Y. F., Fischer, R., Serke, M. H., Gerigk, U., Woempner, C., Krueger, S., Kaminsky, B., Schulte, W., Hoeffken, G., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2015). Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations. Eur. J. Cancer, 51. S. S647 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Golfmann, K., Meder, L., Tharun, L., Dietlein, F., Malcher, F., Koker, M., Buettner, R. and Ullrich, R. T. (2017). Targeting FGFR1 and VEGFR1 displays synergistic treatment effects in FGFR1 overexpressed breast cancer. Oncol. Res. Treat., 40. S. 87 - 88. BASEL: KARGER. ISSN 2296-5262

Goltz, D., Huss, S., Ramadori, E., Buettner, R., Diehl, L. and Meyer, R. (2015). Immunomodulation by splenectomy or by FTY720 protects the heart against ischemia reperfusion injury. Clin. Exp. Pharmacol. Physiol., 42 (11). S. 1168 - 1178. HOBOKEN: WILEY-BLACKWELL. ISSN 1440-1681

Griesinger, F., Buettner, R., Deppermann, K-M, Reinmuth, N., Schuette, W., Thomas, M., Wroblewski, M. and Schumann, C. (2018). Real world molecular testing in patients with EGFR mutation-positive locally advanced or advanced NSCLC in routine practice in Germany - Interim results of the clinical registry PANORAMA. Oncol. Res. Treat., 41. S. 249 - 250. BASEL: KARGER. ISSN 2296-5262

Griesinger, F., Buettner, R., Deppermann, K. -M., Reinmuth, N., Schuette, W., Thomas, M., Bergner, S. and Schumann, C. (2017). PANORAMA - Real world molecular testing, treatment patterns, and clinical outcomes in patients with EGFR mutation-positive locally advanced or advanced NSCLC. Oncol. Res. Treat., 40. S. 248 - 250. BASEL: KARGER. ISSN 2296-5262

Griesinger, F., Buettner, R., Deppermann, K. M., Reinmuth, N., Schuette, W., Thomas, M., Wroblewski, M. and Schumann, C. (2020). Real World Molecular Testing in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC in routine practice in Germany - Interim Results of the clinical registry PANORAMA. Pneumologie, 74. S. S128 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Griesinger, F., Sebastian, M., Serke, M., Buettner, R., Waller, C., Reinmuth, N., Graeven, U., Lueers, A., Radke, S., Karatas, A., Heukamp, L., Tiemann, M. and Overbeck, T. (2015). Induction therapy with intercalated TKI and chemotherapy in NSCLC with activating EGFR mutation in stages II-IIIB: Neolntercal. Oncol. Res. Treat., 38. S. 140 - 141. BASEL: KARGER. ISSN 2296-5262

Hagmeyer, L., Schaefer, S., Fassunke, J., Pietzke-Calcagnile, A., Treml, M., Herkenrath, S. D., Buettner, R. and Randerath, W. J. (2020). Molecular Pathological Analysis in Patients with central Lung Cancer - Endobronchial Ultrasound-guided transbronchial Needle Aspiration and Analysis of circulating Tumor-DNA compared to endobronchial Forceps Biopsy. Pneumologie, 74. S. S129 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Hagmeyer, L., Treml, M., Richter, K., Hekmat, K., Heldwein, M., Schaefer, S., Buettner, R. and Randerath, W. J. (2020). Sensitivity of a PD-L1-Analysis in Patients with non-small cell Lung Cancer (NSCLC) with Pleural Effusion. Pneumologie, 74. S. S40 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Hagmeyer, Lars, Tharun, L., Schaefer, S. C., Hekmat, K., Buettner, R. and Randerath, W. (2017). First case report of a curative wedge resection in epithelial-myoepithelial carcinoma of the lung. Gen. Thorac. Cardiovasc. Surg., 65 (9). S. 535 - 539. TOKYO: SPRINGER JAPAN KK. ISSN 1863-6713

Heukamp, L. C. and Buettner, R. (2013). Genomic analysis of small cell lung cancer - new therapeutic options? Onkologe, 19 (11). S. 958 - 962. NEW YORK: SPRINGER. ISSN 1433-0415

Heydt, C., Baar, T., Wagener, S., Ihle, M. A., Carl, C., Fassunke, J., Buettner, R. and Merkelbach-Bruse, S. (2017). Comparison of custom designed gene panels for hybrid capture-based parallel sequencing in molecular pathology routine diagnostics. J. Mol. Diagn., 19 (2). S. S50 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811

Heydt, C., Pappesch, R., Rehker, J., Wagener, S., Ihle, M. A., Siemanowski, J., Buettner, R., Fassunke, J. and Merkelbach-Bruse, S. (2018). Comparison of DNA- and RNA-based parallel sequencing approaches for the detection of MET Exon 14 skipping mutations. Virchows Arch., 473. S. S288 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Heydt, C., Pappesch, R., Stecker, K., Neumann, J., Buettner, R. and Merkelbach-Bruse, S. (2018). Evaluation of the TruSight Tumor 170 (TST170) assay and its value in clinical research. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Howell, J., Atkinson, S. R., Pinato, D. J., Knapp, S., Ward, C., Minisini, R., Burlone, M. E., Leutner, M., Pirisi, M., Buettner, R., Khan, S. A., Thursz, M., Odenthal, M. and Sharma, R. (2018). Identification of mutations in circulating cell-free tumor DNA as a prognostic biomarker in hepatocellular carcinoma. J. Gastroenterol. Hepatol., 33. S. 29 - 30. HOBOKEN: WILEY. ISSN 1440-1746

Janning, M., Sueptitz, J., Albers-Leischner, C., Delpy, P., Tufman, A., Velthaus-Rusik, J-L, Reck, M., Jung, A., Kauffmann-Guerrero, D., Bonzheim, I, Braendlein, S., Hummel, H-D, Wiesweg, M., Schildhaus, H-U, Stratmann, J. A., Sebastian, M., Alt, J., Buth, J., Esposito, I, Berger, J., Toegel, L., Saalfeld, F. C., Wermke, M., Merkelbach-Bruse, S., Hillmer, A. M., Klauschen, F., Bokemeyer, C., Buettner, R., Wolf, J. and Loges, S. (2022). Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM). Ann. Oncol., 33 (6). S. 602 - 616. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Junker, K., Buettner, R., Langer, T. and Ukena, D. (2018). Pathological-anatomical diagnosis according to the German lung cancer guideline 2018. Pathologe, 39 (6). S. 589 - 604. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Klein, S., Heydt, C., Buettner, R., Hillmer, A. and Drebber, U. (2018). Malignant transformation of a hepatocellular adenoma in a male individual reveals insights into its molecular trajectories. Virchows Arch., 473. S. S124 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Klein, S., Quaas, A., Buettner, R. and Brinker, K. (2018). A word mining approach to select immune-oncological biomarkers. Virchows Arch., 473. S. S19 - 2. NEW YORK: SPRINGER. ISSN 1432-2307

Kloth, M. and Buettner, R. (2016). Where does molecular pathology make sense? Onkologe, 22 (1). S. 13 - 18. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Knittel, G., Korovkina, D., Liedgens, P., Fritz, C., Al-Baldawi, Y., Bahlo, J., Herling, C., Eichhorst, B., Hallek, M., Persigehl, T., Buettner, R. and Reinhardt, H. C. (2016). ESTABLISHMENT OF A PRE-CLINICAL IN VIVO PLATFORM SPANNING LOW-RISK TO HIGH-RISK CLL. Haematologica, 101. S. 9 - 11. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Knittel, G., Korovkina, D., Liedgens, P., Rehkaemper, T., Fritz, C., Torgovnick, A., Al-Baldawi, Y., Al-Maarri, M., Cun, Y., Fedorchenko, O., Riabinska, A., Beleggia, F., Nguyen, P. -H., Wunderlich, F. T., Ortmann, M., Montesinos-Rongen, M., Tausch, E., Stilgenbauer, S., Frenzel, L., Herling, M., Herling, C., Bahlo, J., Hallek, M., Peifer, M., Buettner, R., Persigehl, T. and Reinhardt, H. C. (2017). Novel models of high-risk CLL reveal an actionable PARP1 dependence in ATM-defective CLL in vivo. Oncol. Res. Treat., 40. S. 27 - 28. BASEL: KARGER. ISSN 2296-5262

Knittel, G., Liedgens, P., Korovkina, D., Seeger, J. M., Al-Baldawi, Y., Al-Maarri, M., Fritz, C., Vlantis, K., Bezhanova, S., Scheel, A. H., Wolz, O. -O., Reimann, M., Moeller, P., Lopez, C., Staudt, L. M., Ortmann, M., Pasparakis, M. ORCID: 0000-0002-9870-0966, Siebert, R., Schmitt, C. A., Klatt, A. R., Wunderlich, F. T., Schaefer, S. C., Persigehl, T., Montesinos-Rongen, M., Odenthal, M., Buettner, R., Frenzel, L. P., Kashkar, H. and Reinhardt, H. C. (2016). B cell-specific conditional expression of Myd88 p.L252P leads to the development of diffuse large B cell lymphoma in mice. Oncol. Res. Treat., 39. S. 218 - 220. BASEL: KARGER. ISSN 2296-5262

Knittel, G., Liedgens, P., Korovkina, D., Seeger, J. M., Al-Baldawi, Y., Vlantis, K., Fritz, C., Schaefer, S. C., Klatt, A., Scheel, A., Al-Maarri, M., Bezhanova, S., Montesinos-Rongen, M., Wolz, O. O., Reimann, M., Lohneis, P., Weber, A. N., Wunderlich, F. T., Pasparakis, M. ORCID: 0000-0002-9870-0966, Buettner, R., Persigehl, T., Schmitt, C. A., Odenthal, M., Frenzel, L. P., Kashkar, H. and Reinhardt, H. C. (2016). B CELL-SPECIFIC CONDITIONAL EXPRESSION OF MYD88P.L252P LEADS TO THE DEVELOPMENT OF DIFFUSE LARGE B CELL LYMPHOMA IN MICE. Haematologica, 101. S. 179 - 181. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Koenig, K., Peifer, M., Bos, M., Nogova, L., Merkelbach-Bruse, S., Stamm, K., Henkel, T., Thomas, R., Wolf, J., Buettner, R. and Heukamp, L. (2014). High throughput parallel amplicon sequencing of common driver mutations from FFPE lung cancer samples in molecular pathological routine diagnostics for a regional health care provider network. Oncol. Res. Treat., 37. S. 31 - 33. BASEL: KARGER. ISSN 2296-5262

Koitzsch, U., Heydt, C., Divakar, K., Attig, H., Fassunke, J., Merkelbach-Bruse, S., Fammartino, A. Alessandro, Buettner, R., Kong, Y. and Odenthal, M. (2017). Analysis of Clinical Relevant Mutations by the Novel Gene Reader NGS System. J. Mol. Diagn., 19 (2). S. S55 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811

Koleczko, S., Schaepers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Brandes, V., Abdulla, D., Ueckeroth, F., Thurat, M., Frank, R., Eisert, A., Bitter, E., Woempner, C., Gogl, L., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Koleczko, S., Schapers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Serke, M., Kaminsky, B., Benedikter, J., Bruemmendorf, T. H., Ficker, J. H., Lorenz, J., Schulte, C., Schulze-Olden, S., Brandes, V, Abdulla, D., Ueckeroth, F., Thurat, M., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Oncol. Res. Treat., 39. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Kostenko, A., Kron, F., Michels, S., Fassunke, J., Scheffler, M., Sueptitz, J., Fischer, R., DeMary, P., Glossmann, J. P., Buettner, R. and Wolf, J. (2016). The Network Genomic Medicine first joint cost-effectiveness and outcome evaluation based on multiplex lung cancer genotyping. Oncol. Res. Treat., 39. S. 121 - 122. BASEL: KARGER. ISSN 2296-5262

Kostenko, A., Kron, F., Scheffler, M., Michels, S., Sueptitz, J., Fischer, R., Merkelbach-Bruse, S., Scheel, A., De-Mary, P., Glossmann, J. -P, Buettner, R. and Wolf, J. (2015). Comprehensive multiplex genotyping in lung cancer: challenges and opportunities of interdisciplinary networking using the example of the Network Genomic Medicine. Oncol. Res. Treat., 38. S. 268 - 269. BASEL: KARGER. ISSN 2296-5262

Kostenko, A., Kron, F., Scheffler, M., Michels, S., Sueptitz, J., Fischer, R., Merkelbach-Bruse, S., Scheel, A., De-Mary, P., Glossmann, J. P., Buettner, R. and Wolf, J. (2015). Broad implementation of next generation sequencing based lung cancer genotyping in clinical routine within a nationwide health care provider network in Germany. Eur. J. Cancer, 51. S. S597 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Kostenko, A., Michels, S., Kron, F., Brandes, V, Fischer, R., Nogova, L., Scheffler, M., Fassunke, J., Merkelbach-Bruse, S., Scheel, A., Ueckeroth, F., Sueptitz, J., Gerigk, M., Heydt, C., Glossmann, J. -P, Buettner, R. and Wolf, J. (2016). Improved overall survival following implementation of next generation sequencing in routine diagnostics of advanced lung cancer in Germany: results of the Network Genomic Medicine. Oncol. Res. Treat., 39. S. 305 - 307. BASEL: KARGER. ISSN 2296-5262

Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., Heydt, C., Kron, F., Ueckeroth, F., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Koschel, D., Benedikter, J., Kaminsky, B., Schaaf, B., Braess, J., Sebastian, M., Kambartel, K. -O., Thomas, R., Zander, T., Schultheis, A. M., Buettner, R. and Wolf, J. (2018). Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann. Oncol., 29 (10). S. 2068 - 2076. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Nogova, L., Fischer, R., Ueckeroth, F., Abdulla, D., Kron, F., Pauli, B., Kaminsky, B., Braess, J., Graeven, U., Grohe, C., Krueger, S. ORCID: 0000-0002-1658-5993, Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Ueckeroth, F., Schueller, M., Pauli, B., Grohe, C., Kaminsky, B., Braess, J., Graeven, U., Krueger, S., Nogova, L., Abdulla, D., Fischer, R., Heydt, C., Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF mutated lung cancer patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 247 - 248. BASEL: KARGER. ISSN 2296-5262

Kron, A., Riedel, R., Michels, S., Heydt, C., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Fischer, R., Abdulla, D., Nogova, L., Ueckeroth, F., Pauli, B., Schueller, M., Serke, M., Koschel, D., Krueger, S., Grohe, C., Kambartel, K., Sebastian, M., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation tyrosine kinase inhibitors (TKI) and co-occurring mutations in ALK-positive NSCLC patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 219 - 220. BASEL: KARGER. ISSN 2296-5262

Kron, A., Scheffler, M., Ihle, M., Michels, S., Sueptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R. N., Eisert, A. K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2022). EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB). Ann. Oncol., 33 (7). S. S1006 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Loeser, H., Heydt, C., Buettner, R. and Markiefka, B. (2017). BRCA diagnostics of ovarian cancer. Molecular tumor testing since the introduction of PARP inhibitor therapy. Pathologe, 38 (2). S. 117 - 126. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Meder, L., Koenig, K., Dietlein, F., Florin, A., Koker, M., Buettner, R., Heukamp, L. and Ullrich, R. (2018). LIN28B enhanced tumorigenesis in an autochthonous KRASG12V driven lung carcinoma mouse model. Oncol. Res. Treat., 41. S. 291 - 292. BASEL: KARGER. ISSN 2296-5262

Meder, L., Schuldt, P., Vlasic, I, Volz, C., Golfmann, K., Zaplatina, A., Florin, A., Tharun, L., Buettner, R., Reinhardt, C. and Ullrich, R. (2016). Combining anti-VEGF therapy and immune checkpoint inhibitors improves outcome in small cell lung carcinomas. Oncol. Res. Treat., 39. S. 87 - 88. BASEL: KARGER. ISSN 2296-5262

Meyer, M. F., Kreppel, M., Meinrath, J., Gruunewald, I, Stenner, M., Drebber, U., Quaas, A., Odenthal, M., Semrau, R., Huebbers, C. U., Zoeller, J., Huettenbrink, K-B, Buettner, R. and Beutner, D. (2017). Prediction of outcome by lymph node ratio in patients with parotid gland cancer. Clin. Otolaryngol., 42 (1). S. 98 - 104. HOBOKEN: WILEY. ISSN 1749-4486

Meyer, M. F., Meinrath, J., Seehawer, J., Lechner, A., Odenthal, M., Quaas, A., Semrau, R., Huebbers, C. U., Marnitz, S., Buettner, R. and Beutner, D. (2018). The relevance of the lymph node ratio as predictor of prognosis is higher in HPV-negative than in HPV-positive oropharyngeal squamous cell carcinoma. Clin. Otolaryngol., 43 (1). S. 192 - 199. HOBOKEN: WILEY. ISSN 1749-4486

Michels, S., Brandes, V, Thurat, M., Nogova, L., Scheffler, M., Fischer, R., Merkelbach-Bruse, S., Hellmich, M., Buettner, R. and Wolf, J. (2016). EATON: An open-label, multicenter, phase I dose-escalation trial of EGF816 and trametinib in patients with non-small cell lung cancer and acquired EGFR p.T790M positive resistance to 1st or 2nd generation EGFR TKI therapy - a trial in preparation. Oncol. Res. Treat., 39. S. 172 - 173. BASEL: KARGER. ISSN 2296-5262

Michels, S., Fischer, R., Heydt, C., Ihle, M., Scheffler, M., Scheel, A., Ortiz-Cuaran, S., Nogova, L., Brandes, V, Sos, M., Buettner, R., Merkelbach-Bruse, S. and Wolf, J. (2016). Mechanisms of primary and acquired resistance to 3rd generation EGFR TKI treatment in EGFR mutated lung adenocarcinoma. Oncol. Res. Treat., 39. S. 252 - 254. BASEL: KARGER. ISSN 2296-5262

Michels, S., Gardizi, M., Schultheis, A., Scheffler, M., Karachaliou, N., Teixido, C., Heukamp, L., Merkelbach-Bruse, S., Thurat, M., Nogova, L., Bos, M., Mattonet, C., Grohe, C., Sebastian, M., Thomas, M., Reck, M., Stahel, R., Pirker, R., Zoechbauer-Mueller, S., Groen, H., Dingemanns, A. -M, Smit, E., Thomas, R., Buettner, R., Massuti, B., Rosell, R. and Wolf, J. (2014). EUCROSS: A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262

Michels, S., Plenker, D., Wagener, S., Scheffler, M., Nogova, L., Abdulla, D., Riedel, R., Bunck, A., Merkelbach-Bruse, S., Buettner, R., Sos, M. and Wolf, J. (2017). Loss of ROS1 G2032R resistance mutation upon chemotherapy treatment enables successful crizotinib rechallenge in a ROS1-rearranged NSCLC patient. Oncol. Res. Treat., 40. S. 232 - 233. BASEL: KARGER. ISSN 2296-5262

Michels, S., Schultheis, A., Scheffler, M., Rosner, T., Merkelbach-Bruse, S., Heukamp, L., Engel-Riedel, W., Serke, M., Krueger, S., Benedikter, J., Gerigk, U., Schulte, W., Draube, A., Ko, Y. D., Buettner, R. and Wolf, J. (2014). RET rearrangement in adenocarcinoma of the lung. Oncol. Res. Treat., 37. S. 6 - 7. BASEL: KARGER. ISSN 2296-5262

Michels, S., Thurat, M., Schmalz, P., Pereira, E., Scheffler, M., Fischer, R., Sebastian, M., Abreu, D. R., Carcereny, E., Corral, J. J., Felip, E., Grohe, C., Insa, A., Thomas, M., Reck, M., Rothschild, S., Brandes, V, Nogova, L., Merkelbach-Bruse, S., Massuti, B., Buettner, R., Rosell, R. and Wolf, J. (2016). EUCROSS: A European phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations - Preliminary results. Oncol. Res. Treat., 39. S. 209 - 211. BASEL: KARGER. ISSN 2296-5262

Michels, S., Westphal, T., Nogova, L., Scheffler, M., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Abdulla, D. S. Y., Fischer, R. N., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Weber, J. -P., Fassunke, J., Merkelbach-Bruse, S., Haverkamp, H., Hellmich, M., Buettner, R. and Wolf, J. (2020). EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data. Oncol. Res. Treat., 43 (SUPPL 4). S. 148 - 149. BASEL: KARGER. ISSN 2296-5262

Newell, A. Hanlon, Liu, W., Bubendorf, L., Buettner, R., Kerr, K., Kockx, M., Kossai, M., Lopez-Rios, F., Marchetti, A., Marondel, I., Nicholson, A., Oz, B., Pauwels, P., Penault-Llorca, F., Rossi, G., Russeler, V., Thunnissen, E., Pate, G., Portier, B., Faure, C., Le, C., Smith, D., Menzl, I. and Huang, R. (2018). ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists. J. Thorac. Oncol., 13 (10). S. S452 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Nickel, N., Al-Maarri, M., Pal, M., Roth, A., Schaefer, S., Buettner, R., Hallek, M., Wunderlich, T. and Pallasch, C. P. (2016). AKT activation in Chronic Lymphocytic Leukemia cells promotes transformation towards aggressive Richter's syndrome lymphoma. Oncol. Res. Treat., 39. S. 13 - 14. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Gardizi, M., Bos, M., Scheffler, M., Papachristou, I., Woempner, C., Heukamp, L., Schildhaus, H. -U., Fuhr, U., Sos, M., Eberhardt, W., Wiesweg, M., Schmid, K. W., Schuler, M., Thomas, R., Buettner, R. and Wolf, J. (2014). TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Malchers, F., Bitter, E., Michels, S., Fischer, R., Scheffler, M., Gardizi, M., Brandes, V., Scheel, A. H., Kambartel, K., Krueger, S. ORCID: 0000-0002-1658-5993, Serke, M., Isaacs, R., Porter, D., Buettner, R., Thomas, R. K. and Wolf, J. (2017). Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study: evaluation of tumor tissue and response at a single center. Oncol. Res. Treat., 40. S. 137 - 139. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Malchers, F., Hillmer, A. M., Merkelbach-Bruse, S., Pinto, A., Scheel, A. H., Siemanowski, J., Ueckeroth, F., Scheffler, M., Hummel, H. -D., Kern, J., Wermke, M., Kolbe, M., Grohe, C., Stratmann, J., Sebastian, M., Trummer, A., Weber, J. -P., Westphal, T., Michels, S., Koleczko, S., Sueptitz, J., Keser, E., Kron, A., Riedel, R., Abdulla, D. S. Y., Zadoyan, G., Sweiti, H., Santiago-Walker, A., Rothe, A., Draube, A., Sandler, A., Rodermann, E., Linck, D., Thomas, R. K., Buettner, R. and Wolf, J. (2020). FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC. Oncol. Res. Treat., 43 (SUPPL 4). S. 146 - 148. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Malchers, F., Zadoyan, G., Hillmer, A., Merkelbach-Bruse, S., Riedel, R., Michels, S., Masouleh, Kharabi B., De Porre, P., Santiago-Walker, A., Scheffler, M., Fischer, R. N., Abdulla, D. S. Y., Thomas, R., Buettner, R. and Wolf, J. (2018). FIND trial: a phase II study to evaluate the efficacy of the FGFR-inhibitor erdafitinib in FGFR-mutated and - translocated squamous NSCLC (trial in progress). Oncol. Res. Treat., 41. S. 294 - 295. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Mattonet, C., Gardizi, M., Scheffler, M., Bos, M., Woempner, C., Toepelt, K., Heukamp, L., Suleiman, A., Frechen, S., Soergel, F., Fuhr, U., Schnell, R., Katay, I., Behringer, D., Geist, T., Kaminski, B., Eichstaedt, M., Tummes, D., Buettner, R. and Wolf, J. (2014). SORAVE: Sorafenib and everolimus for patients with solid tumors and with KRAS mutated NSCLC - results of a phase I study. Oncol. Res. Treat., 37. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Ozretic, L., Blau, T., Brunn, A., Buettner, R. and Fries, J. (2016). Multiple organ involvement in IgG4-related disease, misidentified as medical insurance case of asbestosis, leads to sudden death by endocarditis. Virchows Arch., 469. S. S91 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Ozretic, L., Schwindowski, A., Dienes, H. -P., Buettner, R., Drebber, U. and Fries, J. W. U. (2017). Consequences of autopsies for the living. Causes of death in the clinical diagnosis septic and toxic shock. Pathologe, 38 (5). S. 370 - 380. NEW YORK: SPRINGER. ISSN 1432-1963

Ozretic, L., Wagner, S., Huebbers, C. U., Gattenloehner, S., Klussmann, J. P., Beutner, D., Zander, T., Buettner, R. and Quaas, A. (2016). FGFR1 amplification and co-overexpression of c-MYC in oropharyngeal squamous cell carcinoma. Oral Oncol., 54. S. E7 - 3. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1879-0593

Peifer, M., Roels, F., Hertwig, F., Menon, R., Kraemer, A., Buettner, R., Perner, S., Schramm, A., Schulte, J. H., Hero, B., O'Sullivan, R. J., Westermann, F., Thomas, R. K. and Fischer, M. (2015). TELOMERASE ACTIVATION BY RECURRENT GENOMIC REARRANGEMENTS IN HIGH-RISK NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S149 - 2. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017

Porres, D., Pfister, D., Thissen, A., Kuru, T. H., Zugor, V., Buettner, R., Knuechel, R., Verburg, F. A. and Heidenreich, A. (2017). The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. Prostate Cancer Prostatic Dis., 20 (1). S. 85 - 93. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5608

Quaas, A., Schloesser, H., Fuchs, H., Zander, T., Arolt, C., Scheel, A. H., Rueschoff, J., Bruns, C., Buettner, R. and Schroeder, W. . Improved Tissue Processing in Esophageal Adenocarcinoma After Ivor Lewis Esophagectomy Allows Histological Analysis of All Surgically Removed Lymph Nodes with Significant Effects on Nodal UICC Stages. Ann. Surg. Oncol.. NEW YORK: SPRINGER. ISSN 1534-4681

Quaas, A., Waldschmidt, D., Alakus, H., Zander, T., Heydt, C., Goeser, T., Daheim, M., Kasper, P., Plum, P., Bruns, C., Brunn, A., Roth, W., Hartmann, N., Bunck, A., Schmidt, M., Goebel, H., Tharun, L., Buettner, R. and Merkelbach-Bruse, S. (2018). Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel. BMC Gastroenterol., 18. LONDON: BIOMED CENTRAL LTD. ISSN 1471-230X

Rabenhorst, A., Leja, S., Florin, A., Foerster, A., Heukamp, L. C., Ullrich, R. T., Willenborg, S., Eming, S., Buettner, R. and Hartmann, K. (2015). Mast cell-derived vascular endothelial growth factor contributes to tumor growth. J. Invest. Dermatol., 135. S. S19 - 1. NEW YORK: NATURE PUBLISHING GROUP. ISSN 1523-1747

Rabenhorst, A., Leja, S., Florin, A., Heukamp, L. C., Ullrich, R. T., Foerster, A., Roers, A., Buettner, R. and Hartmann, K. (2015). Contribution of mast cell-derived VEGF to tumor growth. Exp. Dermatol., 24 (3). S. E33 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625

Rabenhorst, A., Leja, S., Florin, A., Heukamp, L. C., Ullrich, R. T., Foerster, A., Roers, A., Buettner, R. and Hartmann, K. (2015). Contribution of mast cell-derived VEGF to tumor growth. Exp. Dermatol., 24 (3). S. E33 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625

Rehker, J., Ball, M., Heydt, C., Buettner, R. and Merkelbach-Bruse, S. (2020). Softclipping of gene specific primers after primer extension enrichment to remove artificial sequences from downstream analysis. Eur. J. Hum. Genet., 28 (SUPPL 1). S. 645 - 646. LONDON: SPRINGERNATURE. ISSN 1476-5438

Riabinska, A., Schmitt, A., Fritz, C., Knittel, G., Torgovnick, A., Heneweer, C., Wittersheim, M., Frenzel, L., Wunderlich, C., Jachimowicz, R., Merseburg, A., Persigehl, T., Wunderlich, T., Buettner, R. and Reinhardt, H. C. (2017). Restoration of Atm induces lymphoma regression in vivo and is mediated by cell autonomous and non-cell autonomous mechanisms. Oncol. Res. Treat., 40. S. 40 - 41. BASEL: KARGER. ISSN 2296-5262

Riedel, R., Kron, A., Michels, S., Fassunke, J., Scheffler, M., Fischer, R., Nogova, L., Abdulla, D., Heydt, C., Ueckeroth, F., Pauli, B., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Sebastian, M., Koschel, D., Kambartel, K-O., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Riedel, R., Michels, S., Heydt, C., Nogova, L., Fischer, R. N., Abdulla, D. S. Y., Scheffler, M., Merkelbach-Bruse, S., Kobe, C., Schaefer, S., Buettner, R. and Wolf, J. (2018). Durable response to crizotinib in a patient with lung adenocarcinoma harbouring low-level MET amplification but strong MET expression. Oncol. Res. Treat., 41. S. 295 - 297. BASEL: KARGER. ISSN 2296-5262

Riedel, R., Plenker, D., Michels, S., Nogova, L., Abdulla, D., Scheffler, M., Fischer, R., Brandes, V., Heukamp, L. C., Scheel, A. H., Buettner, R., Sos, M. L. and Wolf, J. (2017). KIF5B-MET fusion genes are novel targets in NSCLC and show sensitivity to MET inhibition with crizotinib. Oncol. Res. Treat., 40. S. 173 - 174. BASEL: KARGER. ISSN 2296-5262

Ruesseler, V., Heydt, C., Binot, E., Bubendorf, L. and Buettner, R. (2018). Testing of ROS1-positive tumours by IHC displays a FISH-positive subgroup which might not benefit form recently approved drug therapy. Virchows Arch., 473. S. S18 - 2. NEW YORK: SPRINGER. ISSN 1432-2307

Scheel, A. H., Dietel, M., Heukamp, L. C., Joehrens, K., Kirchner, T., Reu, S., Rueschoff, J., Schildhaus, H. U., Schirmacher, P., Tiemann, M., Warth, A., Weichert, W., Fischer, R. N., Wolf, J. and Buettner, R. (2016). Predictive PD-L1 immunohistochemistry for non-small cell lung cancer. Current state of the art and experiences of the first German harmonization study. Pathologe, 37 (6). S. 557 - 568. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Scheffler, M., Abdulla, D. S. Y., Koleczko, S., Ihle, M. A., Merkelbach-Bruse, S., Michels, S., Nogova, L., Kron, A., Fischer, R., Serke, M., Ko, Y. -D., Gerigk, U., Schulte, W., Sebastian, M., Riedel, R., Holzem, A., Kambartel, K. -O., Buettner, R. and Wolf, J. (2017). Genetic heterogeneity of KRAS-mutated NSCLC leads to different responses to first-line platinum-based chemotherapy. Oncol. Res. Treat., 40. S. 173 - 174. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Bos, M., Sos, M., Nogova, L., Gardizi, M., Mattonet, C., Papachristou, I., Kahraman, D., Kobe, C., Lammertsma, A., Boellaard, R., Persigehl, T., Heukamp, L., Buettner, R., Elter, T., Toepelt, K., Engel-Riedel, W., Stoelben, E., Neumaier, B., Dietlein, M., Zander, T. and Wolf, J. (2014). MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Heukamp, L., Koenig, K., Serke, M., Nogova, L., Toepelt, K., Stoelben, E., Engel-Riedel, W., Randerath, W., Kaminsky, B., Panse, J., Zander, T., Buettner, R. and Wolf, J. (2014). Clinical and Molecular Characteristics of Non-Small Cell Lung Cancer Patients Harboring PIK3CA Mutations. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Koenig, K., Michels, S., Fassunke, J., Heydt, C., Kuenstlinger, H., Ihle, M. A., Ueckeroth, F., Albus, K., Serke, M., Gerigk, U., Schulte, W., Toepelt, K., Nogova, L., Zander, T., Engel-Riedel, W., Stoelben, E., Ko, Y. -D., Randerath, W. J., Kaminsky, B., Panse, J., Becker, C., Hellmich, M., Merkelbach-Bruse, S., Buettner, R., Heukamp, L. C. and Wolf, J. (2014). Genetic heterogeneity and lack of prognostic impact of patients with non-small cell lung cancer (NSCLC) harboring PIK3CA mutation. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Michels, S., Gardizi, M., Koenig, K., Merkelbach-Bruse, S., Stamm, K., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). DDR2 mutations in non-small cell lung cancer (NSCLC): clinical, histological and genetic characteristics. Oncol. Res. Treat., 37. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Nogova, L., Michels, S., Holzem, A., Chanra, T., Abdulla, D. S. Y., Koleczko, S., Merkelbach-Bruse, S., Fassunke, J., Kron, A., Scheel, A. H., Ihle, M. A., Heydt, C., Westphal, T., Weber, J. -P., Fischer, R. N., Riedel, R., Kaminsky, B., Draube, A., Rothe, A., Kambartel, K. -O., Hillmer, A., Buettner, R. and Wolf, J. (2020). KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup. Oncol. Res. Treat., 43 (SUPPL 4). S. 139 - 140. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Schultheis, A., Michels, S., Teixido, C., Hartmann, W., Merkelbach-Bruse, S., Sebastian, M., Serke, M., Kropf-Sanchen, C., Wittersheim, M., Puetz, K., Binot, E., Schildhaus, H. -U., Heukamp, L. C., Rosell, R., Buettner, R. and Wolf, J. (2014). ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability. Oncol. Res. Treat., 37. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262

Schlesinger, A., Meisen, A., Mueller-Huebenthal, J., Buettner, R., Angenendt, S. and Beckers, F. (2020). Sensitivity and Specificity of EBUS/PET-Ct/Surgery for Patients with N2-Disease - retrospective 1-Year-Single-Center-Analysis. Pneumologie, 74. S. S53 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Schmitt, A., Knittel, G., Welcker, D., Yang, T. -P., George, J., Nowak, M., Leeser, U., Buettner, R., Perner, S., Peifer, M. and Reinhardt, H. C. (2017). ATM deficiency is associated with sensitivity to PARP1-and ATR inhibitors in lung adenocarcinoma. Oncol. Res. Treat., 40. S. 247 - 248. BASEL: KARGER. ISSN 2296-5262

Schneider, R., Schneider, C., Buettner, R., Reinacher-Schick, A., Tannapfel, A., Fuerst, A., Rueschoff, J., Jakobeit, C., Royer-Pokora, B. and Moeslein, G. (2015). Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm. Zent.bl. Chir., 140 (6). S. 591 - 600. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-9592

Schoemmel, M., Loeser, H., Kraemer, M., Wagener-Ryczek, S., Hillmer, A., Bruns, C., Thelen, M., Schroeder, W., Zander, T., Lechner, A., Buettner, R., Schloesser, H., Gebauer, F. and Quaas, A. (2021). Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus. Clin. Transl. Oncol., 23 (8). S. 1601 - 1611. CHAM: SPRINGER INT PUBL AG. ISSN 1699-3055

Surowy, H. M., Giesen, A. K., Otte, J., Buettner, R., Falkenstein, D., Friedl, H., Meier, F., Petzsch, P., Wachtmeister, T., Westphal, D., Wieczorek, D., Wruck, W., Adjaye, J., Ruetten, A. and Redler, S. (2019). Gene expression profiling in aggressive digital papillary adenocarcinoma sheds light on the architecture of a rare sweat gland carcinoma. Br. J. Dermatol., 180 (5). S. 1150 - 1161. HOBOKEN: WILEY. ISSN 1365-2133

Thewes, V., Simon, R., Hlevnjak, M., Schlotter, M., Schroeter, P., Schmidt, K., Wu, Y., Anzeneder, T., Wang, W., Windisch, P., Kirchgaessner, M., Melling, N., Kneisel, N., Buettner, R., Deuschle, U., Sinn, H. P., Schneeweiss, A., Heck, S., Kaulfuss, S., Hess-Stumpp, H., Okun, J. G., Sauter, G., Lykkesfeldt, A. E., Zapatka, M., Radlwimmer, B., Lichter, P. and Toenjes, M. (2017). The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ER alpha-negative breast cancer. Oncogene, 36 (29). S. 4124 - 4135. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5594

Thomalla, D., Beckmann, L., Grimm, C., Oliverio, M., Meder, L., Herling, C. D., Nieper, P., Feldmann, T., Merkel, O., Lorsy, E., Guerreiro, A. da Palma, von Jan, J., Kisis, I., Wasserburger, E., Claasen, J., Faitschuk-Meyer, E., Altmueller, J., Nuernberg, P., Yang, T. -P., Lienhard, M., Herwig, R., Kreuzer, K. -A., Pallasch, C. P., Buettner, R., Schaefer, S. C., Hartley, J., Abken, H., Peifer, M., Kashkar, H., Knittel, G., Eichhorst, B., Ullrich, R. T., Herling, M., Reinhardt, H. C., Hallek, M., Schweiger, M. R. and Frenzel, L. P. (2022). Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood, 140 (20). S. 2113 - 2127. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Thunnissen, E., Lissenberg-Witte, B., Van den Heuvel, M., Monkhorst, K., Skov, B., Sorensen, J., Mellemgaard, A., Dingemans, A., Speel, E., De langen, J., Hashemi, S., Bahce, I., Van Der Drift, M., Buettner, R., Salomon, M. Looijen, Gosney, J., Postmus, P. E., Samii, S., Duplaquet, F., Weynand, B., Durando, X., Penault-Llorca, F., Finn, S., Oz, B., Akyurek, N., Wolf, J., Bubendorf, L., Hiemstra, A., Duin, S., Marondel, L., Timens, W., Schuuring, E., Pauwels, P. and Smit, E. (2018). Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative. J. Thorac. Oncol., 13 (10). S. S452 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Thunnissen, E., Lissenberg-Witte, B., I, van den Heuvel, M. M., Monkhorst, K., Skov, B. G., Sorensen, J. B., Mellemgaard, A., Dingemans, A. M. C., Speel, E. J. M., de Langen, A. J., Hashemi, S. M. S., Bahce, I, van der Drift, M. A., Looijen-Salamon, M. G., Gosney, J., Postmus, P. E., Samii, S. M. S., Duplaquet, F., Weynand, B., Durando, X., Penault-Llorca, F., Finn, S., Grady, A. O., Oz, B., Akyurek, N., Buettner, R., Wolf, J., Bubendorf, L., Duin, S., Marondel, I, Heukamp, L. C., Timens, W., Schuuring, E. M. D., Pauwels, P. and Smit, E. F. (2019). ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer, 138. S. 13 - 19. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-8332

Tischler, V., Ihle, M. A., Stenzinger, A., Weichert, W., Jochum, W., Buettner, R., Wolf, J., Peifer, M. and Thomas, R. (2018). Clonal and subclonal occurrence of oncogenic mutations in lung adenocarcinoma. J. Thorac. Oncol., 13 (4). S. S12 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Trautmann, M., Sievers, E., Aretz, S., Kindler, D., Michels, S., Friedrichs, N., Renner, M., Kirfel, J., Steiner, S., Huss, S., Koch, A., Penzel, R., Larsson, O., Kawai, A., Tanaka, S., Sonobe, H., Waha, A., Schirmacher, P., Mechtersheimer, G., Wardelmann, E., Buettner, R. and Hartmann, W. (2014). SS18-SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene, 33 (42). S. 5006 - 5017. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5594

Vergote, I, Gonzalez-Martin, A., Ray-Coquard, I, Harter, P., Colombo, N., Pujol, P., Lorusso, D., Mirza, M. R., Brasiuniene, B., Madry, R., Brenton, J. D., Ausems, M. G. E. M., Buettner, R. and Lambrechts, D. (2022). European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann. Oncol., 33 (3). S. 276 - 288. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Vogel, Y., Wolff, I., Zienkiewicz, T., Buettner, R. and Schulte, W. (2014). A very rare cause of haemoptysis - coexistence of primary oncocytic adenoma of trachea with bronchial carcinoma. Dtsch. Med. Wochenschr., 139 (24). S. 1295 - 1299. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413

Vollbrecht, C., Koenig, K., Heukamp, L. C., Peifer, M., Buettner, R., Odenthal, M. and Schweighofer, C. D. (2014). Detection of hot spot and pathway related variants in chronic lymphocytic leukemia by multiplexed amplicon sequencing. Eur. J. Cancer, 50. S. S145 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Vollbrecht, C., Koitzsch, U., Koenig, K., Kloth, M., Buettner, R. and Odenthal, M. (2014). Process-automation of next generation sequencing for high-throughput mutation analyses in cancer. Eur. J. Cancer, 50. S. S93 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Vollbrecht, C., Mairinger, F. D., Koitzsch, U., Peifer, M., Koenig, K., Heukamp, L., Crispatzu, G., Wilden, L., Kreuzer, K-A, Hallek, M., Odenthal, M., Herling, C. D. and Buettner, R. (2016). Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing. Oncol. Res. Treat., 39. S. 159 - 160. BASEL: KARGER. ISSN 2296-5262

Vollbrecht, C., Mairinger, F. D., Schweighofer, C. D., Heukamp, L. C., Merkelbach-Bruse, S., Buettner, R. and Odenthal, M. (2014). Testing cancer related gene panels for high throughput parallel sequencing. Eur. J. Cancer, 50. S. S145 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Volz, C., Zaplatina, A., Siobal, M., Chatterjee, S., Schoettle, J., Meder, L., Florin, A., Koker, M., Buettner, R., Miao, H., Wang, B., Hallek, M., Acker-Palmer, A. S., Heukamp, L. C., Thomas, R. K. and Ullrich, R. (2016). Anti angiogenic treatment induces tumor cell invasion and metastasis via EphA2 signaling in NSCLC. Oncol. Res. Treat., 39. S. 88 - 89. BASEL: KARGER. ISSN 2296-5262

Wagener, S., Ihle, M. A., Alidousty, C., Heydt, C., Fassunke, J., Merkelbach-Bruse, S. and Buettner, R. (2018). The potential biomarkerHR23b regulates sensitivity towards histone deacetylase inhibitors (HDACi) via the NGFR death receptor pathway. Virchows Arch., 473. S. S1 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Wang, L., Yu, X., Schmiel, M., Steinheuer, L., Eischeid, H., Ulmer, B., Buettner, R. and Odenthal, M. (2018). The impact of the epigenetic writer LSD1 in the cell cycle control in liver fibrosis and hepatocellular carcinoma. J. Hepatol., 68. S. S690 - 1. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1600-0641

Weber, J. -P., Fischer, R. N., George, J., Scheel, A., Westphal, T., Koleczko, S., Nogova, L., Riedel, R., Michels, S., Scheffler, M., Abdullah, D. S. Y., Sueptitz, J., Keser, E., Merkelbach-Bruse, S., Pinto, A., Buettner, R., Thomas, R. and Wolf, J. (2020). Small Cell Lung Cancer - Filling the gap between science and patients. Oncol. Res. Treat., 43 (SUPPL 4). S. 154 - 155. BASEL: KARGER. ISSN 2296-5262

Wedemeyer, I., Kreppel, M., Scheer, M., Zoeller, J. E., Buettner, R. and Drebber, U. (2014). Histopathological assessment of tumour regression, nodal stage and status of resection margins determines prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. Oral Dis., 20 (3). S. e81 - 9. HOBOKEN: WILEY. ISSN 1601-0825

Wittersheim, A. I., Boell, B., Shimabukuro-Vomhagen, A., Castiglione, R., Blau, T., ten Freyhaus, H., Schultheis, A. M., Buettner, R. and Schaefer, S. C. (2016). Extensively metastasized cardiac angiosarcoma mimicking systemic sarcoidosis. Virchows Arch., 469. S. S242 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Wittersheim, Maike, Schallenberg, S. and Buettner, R. (2018). Non-small cell lung cancer-pathology and biology. Onkologe, 24 (12). S. 958 - 967. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Wolf, J., Baik, C., Heist, R. S., Neal, J. W., Mansfield, A. S., Buettner, R., Davis, K. L., Giovannini, M., Mutebi, A. and Awad, M. M. (2018). Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts). Eur. J. Cancer, 103. S. E131 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Wuerdemann, N., Gueltekin, S. E., Wittekindt, C., Sharma, S. J., Schubotz, A. B., Gattenloehner, S., Tharun, L., Baris, E., Sengueven, B., Yildirim, B., Buettner, R., Speel, E. -J., Wagner, S., Klussmann, J. -P. and Quaas, A. (2018). Expression of Programmed Death-Ligand 1 and 2 (PD-L1/2) on Tumor cells of Oropharyngeal Squamous Cell Carcinoma (OPSCC). Oncol. Res. Treat., 41. S. 95 - 96. BASEL: KARGER. ISSN 2296-5262

von Laffert, M., Schirmacher, P., Warth, A., Weichert, W., Buettner, R., Huber, R. M., Wolf, J., Griesinger, F., Dietel, M. and Grohe, C. (2016). Statement of the GSP and the WG Thoracic Oncology of the WG Oncology/German Cancer Society e. V. on ALK-Testing in the NSCLC Immunohistochemistry and/or FISH? Pathologe, 37 (2). S. 187 - 192. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

von Laffert, M., Schirmacher, P., Warth, A., Weichert, W., Buettner, R., Huber, R. M., Wolf, J., Griesinger, F., Dietel, M. and Grohe, Ch. (2016). ALK-Diagnostics in non-small cell Lung Cancer (NSCLC) - Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)? Statement of the German Society for Pathology and the WG Thoracic Oncology of the Working Group Oncology/German Cancer Society e.V. Pneumologie, 70 (4). S. 277 - 282. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

von Laffert, M., Schirmacher, P., Warth, A., Weichert, W., Buettner, R., Huber, R. M., Wolf, J., Griesinger, F., Dietel, M. and Grohe, Ch. (2017). ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)? Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft fur Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.). Lung Cancer, 103. S. 1 - 6. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-8332